Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms-Reference-Cited by-同舟云学术

Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms

Published:2021-06-24 Issue:6 Volume:194 Page:1010-1015
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Chowdhury Onima¹²³^ORCID,Bruguier Hannah³,Mallett Garry³,Sousos Nikolaos¹²³^ORCID,Crozier Kirsty³,Allman Caroline³,Eyre David⁴⁵,Lumley Sheila⁵⁶,Strickland Marie¹²,Karali Christina S.¹²,Murphy Lauren¹²,Sternberg Alex³,Jeffery Katie⁵,Mead Adam J.¹²³^ORCID,Peniket Andy³,Psaila Bethan¹²³^ORCID

Affiliation:

1. MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine University of Oxford OxfordUK

2. National Institute of Health Research Oxford Biomedical Research Centre OxfordUK

3. Department of Haematology Churchill Hospital Oxford University Hospitals’ NHS Foundation Trust OxfordUK

4. Nuffield Department of Population Health Big Data Institute University of Oxford OxfordUK

5. Department of Microbiology Oxford University Hospitals’ NHS Foundation Trust OxfordUK

6. Nuffield Department of Medicine University of Oxford Oxford UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17644

Reference11 articles.

1. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

2. Factors associated with COVID-19-related death using OpenSAFELY

3. Results of a national UK physician reported survey of COVID‐19 infection in patients with a myeloproliferative neoplasm;Salisbury RA;Leukemia,2021

4. Interim results of the safety and immune‐efficacy of 1 versus 2 doses of COVID‐19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines;Monin‐Aldama L;medRxiv,2021

5. Quantitative SARS‐CoV‐2 anti‐spike responses to Pfizer‐BioNTech and Oxford‐AstraZeneca vaccines by previous infection status;Eyre DW;medRxiv,2021

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis;JMA Journal;2024

2. Supportive Care for Patients With Myelodysplastic Syndromes;The Cancer Journal;2023-05

3. Risk factors and outcomes of COVID‐19 in adult patients with hematological malignancies: A single‐center study showing lower than expected rates of hospitalization and mortality;European Journal of Haematology;2023-04-24

4. Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis;Cancers;2023-04-12

5. Adverse Hematological Effects of COVID-19 Vaccination and Pathomechanisms of Low Acquired Immunity in Patients with Hematological Malignancies;Vaccines;2023-03-15